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Abstract
Background: Alcoholic steatohepatitis (ASH) is a serious complication of alcoholic liver disease. The diagnosis of
ASH requires the association of steatosis, evidence of hepatocellular injury with ballooning degeneration, and
polynuclear neutrophil infiltration on liver biopsy. Whether these lesions, in addition to other histological features
observed in liver tissue specimens, have prognostic significance is unclear.
Methods: We studied 163 patients (age 55 yrs [35-78], male/female 102/61) with recent, heavy (> 80 gr/day)
alcohol intake, histologically-proven ASH (97% with underlying cirrhosis, Maddrey’s score 39 [13-200], no sepsis),
who had a liver biopsy performed 3 days [0-10] after hospital admission for clinical decompensation. A semi-
quantitative evaluation of steatosis, hepatocellular damage, neutrophilic infiltration, periportal ductular reaction,
intraparenchymal cholestasis, and iron deposits was performed by two pathologists. All patients with a Maddrey’s
score ≥ 32 received steroids. The outcome at 3 months was determined. Statistical analysis was performed using
the Wilcoxon and Fisher’s exact tests, Kaplan-Meier method, and the Cox proportional hazard model.
Results: 43 patients died after 31 days [5-85] following biopsy. The 3-month survival rate was 74%. Mean kappa
value for histological assessment by the two pathologists was excellent (0.92). Univariate analysis identified age, the
Maddrey’s score, the Pugh’s score, the MELD score and parenchymal cholestasis, but not other histological features,
as factors associated with 3-month mortality. At multivariate analysis, age (p = 0.029, OR 2.83 [1.11-7.2],
intraparenchymal cholestasis (p = 0.001, OR 3.9 [1.96-7.8], and the Maddrey’s score (p = 0.027, OR 3.93 [1.17-13.23]
were independent predictors of outcome. Intraparenchymal cholestasis was more frequent in non survivors
compared to survivors (70% versus 25%, p < 0.001). Serum bilirubin was higher in patients with severe compared
to those with no or mild intraparenchymal cholestasis (238 [27-636] versus 69 [22-640] umol/l, p < 0.001).
Conclusions: In this large cohort of patients with histologically documented ASH early after admission and no
sepsis, liver biopsy identified marked intraparenchymal cholestasis as an independent predictor of poor short term
outcome together with age and the Maddrey’s score. It may be hypothesized that incorporation of this particular
variable into existing disease severity scores for ASH would improve their performance.
Background
Alcoholic steatohepatitis (ASH) is an acute inflamma-
tory liver disease associated with a poor outcome [1]. In
patients with a severe form of ASH, as defined by a
Maddrey’s score (also reported as Maddrey’s discrimi-
nant function) ≥ 32, a 4-week course of corticosteroids
significantly reduces the short-term mortality by
approximately 25% [2].
Decompensated cirrhosis is a common clinical presenta-
tion of ASH in Western Europe [1], but the diagnosis of
ASH using only clinical and biological criteria is very chal-
lenging for the physician. Accordingly, ASH but also other
situations such as infection, gastrointestinal bleeding, or
drug-induced hepatitis are common precipitants of acute
deterioration in patients with alcoholic cirrhosis, a condi-
tion referred to as acute-on-chronic liver failure [3].
Therefore, when a severe form of ASH is suspected, as
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assessed by the Maddrey’s discriminant function [2] or the
MELD score [4], a liver biopsy is strongly recommended
to make a definite diagnosis and to guide steroid therapy.
Histologically, ASH is defined by the presence of stea-
tosis (macro- and/or microvesicular), hepatocellular
injury (ballooning, apoptosis), and infiltration of the liver
lobule by polynuclear neutrophils[5]. Mallory-Denk hya-
line bodies, megamitochondria, perisinusoidal fibrosis,
mild iron deposits, some degree of ductular reaction (also
described as cholangiolar proliferation corresponding to
proliferation of hepatic progenitors[6]), and intrapar-
enchymal cholestasis are also described[7,8] but not
required for diagnosis. Equivalent terms used for intra-
parenchymal cholestasis include bile pigments accumula-
tion, bilirubinostasis, intralobular cholestasis or
cholestatic alcoholic hepatitis[6,7,9]. Liver biopsy is
mostly performed in patients with presumed ASH to
exclude other causes of liver disease and to confirm the
presence of ASH. Whether the full spectrum of histologi-
cal alterations observed in liver biopsies of patients with
ASH has a clinical significance remains unclear[7]. Thus,
the aim of this study was to explore the prognostic value
of several histological features observed on liver biopsy
performed early after hospital admission in a large num-
ber of patients with recent active alcohol intoxication,
documented ASH and no associated sepsis.
Methods
Patients
The study population included 163 patients with ASH
admitted to our institution between April 2004 and
April 2007, selected according to the algorithm provided
in Figure 1. One hundred and forty two patients were
selected from control arms of previous interventional or
observational cohorts[10-12] and 21 patients had a liver
biopsy performed as part of the diagnostic work-up of
an acute deterioration of liver function in patients with
alcoholic liver disease. In all cases, the purpose of liver
biopsy was to confirm a presumed diagnosis of ASH.
To be eligible, patients had to present with a history of
heavy recent alcohol intake (> 80 gr per day), no radiolo-
gical evidence of bile duct alterations, no documented
hepatocellular carcinoma, no positive serology for hepati-
tis A, B, C or HIV, no disease associated with iron over-
load and no documented infection at the time of hospital
admission and of liver biopsy. The main reason for
excluding patients with concomitant infection is the
commonly accepted role of sepsis-associated cholestasis
[13] as a confounding factor for the histological analysis.
In addition, infection in decompensated cirrhotic patients
with ASH is a major determinant of poor outcome [14].
Therefore, infection was actively sought in all patients at
time of hospital admission, as recommended [15]. The
Figure 1 Flowchart of patients’ selection. Abbreviation: DF: discriminant function.
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evaluation included a diagnostic paracentesis, urine and
blood cultures, and a chest radiograph. A neutrophil
count > 250/mm3 in ascites, whether or not associated
with a positive culture, was diagnosed as a spontaneous
bacterial peritonitis and considered an exclusion criter-
ion. Similarly, patients with microbiological evidence of
infection in urine or blood, or with a pulmonary infiltrate
on chest X-ray were not eligible for the analysis. During
follow-up, patients were monitored closely for signs of
infection, in particular for spontaneous bacterial peritoni-
tis as the most common site of infection in this patient
population [15] and received immediate broad-spectrum
antibiotics in case of confirmation of diagnosis. Patients
who received steroids were also administered preventive
antibiotherapy with daily oral norfloxacin, in accordance
to local guidelines. The diagnosis of ASH was based on
histology in all patients, and the biopsy was performed
early after hospital admission. All patients received stan-
dard medical care including nutritional therapy and sup-
port regarding alcohol abstinence during follow-up, as
recommended[16]. Patients with ASH and a Maddrey’s
score ≥ 32 or a MELD score ≥ 18 were identified as high
risk for short-term mortality[4,17] and were all treated by
prednisone 40 mg daily for 28 days[2] in addition to stan-
dard medical therapy. Patients’ characteristics are sum-
marized in table 1.
During this period, 71 patients with ASH were not
included due to concomitant bacterial infection identified
at hospital admission (n = 12), coexistent viral hepatitis
or HIV (n = 15), radiological evidence of bile duct disease
(n = 16), multifocal hepatocellular carcinoma (n = 21) or
because of incomplete follow-up (n = 7)(see Figure 1).
Liver biopsy
It is our policy to perform a liver biopsy early in the
course of hospitalization in patients with decompensated
alcoholic liver disease and suspicion of ASH.
The liver biopsy was performed after a median time of
3 days after admission (range: 0-10 days), either percuta-
neously (Hepafix Liver biopsy set 17G, Braun
Melsungen, Germany) or via the transjugular route
(TJL-101-ET needle set, Cook Europe, Bjaeverskov, Den-
mark) depending on the presence of coagulopathy and/
or ascites. The liver biopsy specimen was placed into
formalin 10%, then fixed and embedded in a paraffin
wax block to be processed for light microscopy. Serial
sections were stained with haematoxylin-eosin, reticulin,
Masson Trichrome and Pearl’s coloration for iron.
The entire liver biopsy specimen was examined by using
20-50 high-power fields (x 400), as previously described
[18]. Histopathological studies were performed by two
pathologists (LRB and MG) experts in liver diseases,
who were unaware of patients’ characteristics and
outcome. The diagnosis of ASH was based on the coex-
istence of steatosis, ballooning degeneration of hepato-
cytes, and lobular infiltration with polynuclear
neutrophils[5]. Additional features including fibrosis,
Mallory-Denk hyaline bodies, iron deposits, ductular
proliferation in the periportal areas, and intraparenchy-
mal cholestasis were also carefully examined. We
restricted our analysis of cholestasis to the lobular area,
however we did not consider ductular bilirubinostasis in
the periportal areas as it has been previously described
to be associated with sepsis[13]. Thus, our analysis was
focused on the presence of bile pigments (or bile plugs)
in hepatocytes.
We assessed the intensity of individual lesions using a
semi-quantitative score. Thus, a score of 1 or 0 was given
if the histological lesion was present in > 50% or < 50% of
all microscopic fields, respectively. Due to the possible
influence of subjective interpretation by observers, the two
histopathologists were asked to determine lesion intensity
for each biopsy specimen in a blinded manner.
We arbitrarily chose to group hepatocyte ballooning and
Mallory-Denk hyaline bodies under the term “hepatocellu-
lar damage” and macrovesicular and microvesicular steato-
sis under the term “steatosis”. Due to the high prevalence
(> 95%) of cirrhosis in our patient population, we decided
not to take fibrosis into consideration. Thus, the following
histological features were considered for the analysis: stea-
tosis, hepatocellular damage, neutrophilic infiltration,
ductular reaction, intraparenchymal cholestasis, and iron
deposits.
Biological values
All scores (Child-Pugh’s score, Maddrey’s and the MELD
score) were obtained using variables measured at the
time of liver biopsy. The variables taken into considera-
tion in these scores include coagulation parameters and
serum bilirubin, as well as creatinine in the MELD score
[1]. Serological status for hepatitis A, B and C was deter-
mined at admission. Patients with excessive iron deposits
on liver biopsy were studied for the C282Y HFE gene
mutation to rule out hereditary hemochromatosis.
Table 1 Patients characteristics
variable n median range
Gender (M/F) 102/61
Age (yrs) 55 35-78
Child-Pugh’s score 10 6-14
MELD score 18.5 7-37
Maddrey’s score 39 13-200
Serum bilirubin (μmol/l) 91 17-636
Blood leucocytes (G/l) 7.4 5-18.3
Neutrophils (G/l) 6.2 3.8-15.2
ASAT (IU/l) 90 47-192
Alkakine phosphatase (IU/l) 160 89-239
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We used TNFa and soluble form of the receptor 1 for
TNFa (sTNF-R1) serum values measured in a subgroup
of patients from a previous study[11] to explore the
relationship between these pro inflammatory cytokines
and intraparenchymal cholestasis.
Outcome
We determined the patients’ clinical outcome over a 3-
month follow-up period starting from the time of liver
biopsy, using hospital records and clinical information
obtained from the general practitioners. In case of death,
the cause was identified.
Ethical considerations
The study protocol was approved by the Institutional
Review Board of the Hôpitaux Universitaires de Gen-
ève who allowed us to retrospectively analyze the his-
tological, biological and clinical data of the study
population.
Statistical analysis
Variables are given either as categorical (histological fea-
tures) or continuous (age, bilirubin) values, and
expressed as median and ranges. Rating for continuous
variables was determined according to median value in
the group. The Wilcoxon and Fisher’s exact tests were
used to compare variables between groups. Inter-rater
agreement for qualitative variables was assessed with K
statistics. A kappa value greater than or equal to 0.75
was considered to represent good agreement. Patients’
survival was analyzed by the Kaplan-Meier method. The
prognostic significance of the variables in the univariate
analysis was determined using the log rank test. Rating
for each variable was determined according to the med-
ian value in the group. To identify independent predic-
tors of mortality at 3 months, we performed a
multivariate logistic regression analysis using a Cox pro-
portional hazard model. A 2-sided P value of < 0.05 was
considered statistically significant. All statistical tests
were performed by using the Statistical Package for the




Thirty patients (18%) returned to some degree of alco-
hol consumption during follow-up. Overall survival rate
in this cohort of patients with predominant severe ASH
was 74%. Over a 3-month period following liver biopsy,
43 patients, including 39 with severe ASH, died at a
median time of 31 days (range: 4-85 days) following
liver biopsy. The causes of death were progressive liver
insufficiency (n = 19), infection (n = 11), portal hyper-
tensive bleeding (n = 8), and others (n = 5).
Histological features
The liver biopsy was performed percutaneously in 31
patients and via the transjugular route in 132 patients,
without major complications. Despite a high rate of tissue
fragmentation due to cirrhosis in the vast majority of
cases, the mean size of liver biopsy specimens was 19
[13-38] mm in length, allowing an accurate histological
interpretation in all cases[19]. All patients fulfilled the
criteria for ASH[5]. Additional features observed in >
50% of the biopsy specimen, and therefore considered to
be severe according to our definition, are summarized in
Figure 2. Thus, 97% of patients had severe fibrosis reach-
ing the stage of cirrhosis, 64% demonstrated major stea-
tosis, 70% had extensive hepatocellular damage, 55%
showed important neutrophilic infiltrates, 37% had a
marked periportal ductular reaction, 39% presented with
severe intraparenchymal cholestasis, and 15% showed
increased iron deposits that predominated in non par-
enchymal cells. Typical appearance of severe intrapar-
enchymal cholestasis is illustrated in Figure 3.
Histological characteristics of survivors and non survi-
vors are provided in table 2. Intraparenchymal cholestasis,
but no other histological features, was significantly more
frequent in patients with ASH who died during follow-up
as compared to survivors. Cumulative survival according
to severity of intraparenchymal cholestasis is illustrated in
Figure 4.
Univariate analysis
Univariate analysis (table 3) identified age, the Mad-
drey’s score, the Pugh’s score, the MELD score and par-
enchymal cholestasis, but not ASAT, alkaline
phosphatase, nor other histological features, as factors
associated with mortality at 3 months.
Figure 2 Prevalence (expressed in percent of patients) of
histological features that were severe in intensity, observed in
163 patients with ASH.
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Multiple regression analysis
Continuous (age, serum creatinine, bilirubin) and categori-
cal variables (histological features), were incorporated into
the statistical model. As the Maddrey’s score determined
steroid treatment in all patients, treatment with steroids
per se was not included in the model as a variable. Results
are given in table 4. At multivariate analysis, age (p =
0.029, OR 2.83 [1.11-7.2] and histological cholestasis (p =
0.001, OR 3.9 [1.95-7.8] were independent predictors of
outcome.
Correlations
Patients with ASH and marked histological cholestasis
on liver biopsy demonstrated higher serum bilirubin
values compared to those without histological cholesta-
sis (238 [27-636] vs 69 [22-640] μmol/l, p < 0.0001).
Although the difference was highly significant, serum
bilirubin values were distributed over a wide range in
patients with marked lobular cholestasis (see Figure 5),
and 27 patients (16.5%) with serum bilirubin exceeding
100 umol/l had no or mild cholestasis.
Serum values of TNFa and sTNF-R1 were available in
20 patients with cholestasis and 31 patients without
cholestasis. In these patients, neither TNFa (7.1 [2-13]
vs 5.3 [1-17.3] pg/ml, p = 0.53) nor sTNF-R1 (4600
[1000-8400] vs 2400 [300-7000] pg/ml, p = 0.15) serum
values were different between groups.
Discussion
The prominent finding of this large retrospective study is
the presence of marked intraparenchymal cholestasis on
liver biopsy as an independent predictor of survival,
along with age and the Maddrey’s score. Among other
histological lesions commonly observed in ASH[20] bilir-
ubinostasis was also the sole predictor of outcome. Inter-
pretation of intrahepatic cholestasis is especially
challenging in patients with decompensated cirrhosis at
risk of developing biliary tract disease, infection or sepsis.
In the latter situation, intrahepatic cholestasis is a promi-
nent finding[13]. Having reasonably excluded the role of
bile duct lesions or concomitant sepsis with the complete
work-up performed at admission, intraparenchymal cho-
lestasis can be considered as a lesion associated with
ASH, as previously suggested[21]. Our results are in line
with the study by Nissenbaum et al.[9] who reported lob-
ular cholestasis in 38% of patients that correlated to mal-
nutrition and a poor clinical outcome. In a recent cohort
of alcoholics presenting as acute-on-chronic liver failure
[6], a majority of whom reached the histological criteria
for ASH, bilirubinostasis within the ductular reaction
predicted in-hospital mortality. In this study, however,
Figure 3 Representative illustration of marked intraparenchymal
cholestasis in a patient with alcoholic steatohepatitis
(Haematoxylin-eosin stain, original magnification × 400). Arrows
indicate bile plugs located in the liver parenchyma.
Table 2 Histological features on liver biopsy according to clinical outcome
Survivors (n = 120) Non survivors (n = 43) p value
Steatosis 69 (58%) 35 (81%) 0.4
Polynuclear neutrophils 66 (66%) 25 (60%) 0.9
Hepatocellular damage 80 (69%) 35 (81%) 0.8
Ductular reaction 47 (40%) 14 (32%) 0.9
Intraparenchymal cholestasis 31 (25%) 32 (70%) 0.001
Iron deposits 16 (14%) 9 (21%) 0.5
Figure 4 Kaplan-Meier survival curve according to severity of
intraparenchymal cholestasis on liver biopsy from 163 patients
with ASH.
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infection was documented in a substantial number of
patients at time or very early (< 48 h) after hospital
admission, and thus a role for sepsis in the development
of intrahepatic cholestasis is difficult to rule out[13]. In
our study, having excluded patients with sepsis at admis-
sion and focused our analysis to cholestasis in the liver
lobule, we believe our data truly reflect lesions associated
with ASH. Nevertheless, eleven patients (4%) developed
infection during follow-up and died of sepsis, a frequent
complication of severe ASH treated with steroids[15].
This incidence is low compared to recent data[14], and
may result from a proportion of non severe ASH in our
cohort as well as the implementation of antibioprophy-
laxis in steroid-treated patients.
The development of jaundice and elevated serum bilir-
ubin is common in decompensated alcoholic liver disease
associated with ASH[1]. Accordingly, serum bilirubin is
integrated in several prognostic models[4,17,22] that
guide therapeutic decisions. In our study, most patients
with high serum bilirubin, but not all, showed marked
lobular cholestasis. Nevertheless, our data are in line with
results from previous studies[6,9,21] suggesting that his-
tology provides additional prognostic information.
The pathophysiology of cholestasis in ASH is still
uncertain. Proposed mechanisms include compression
of intrahepatic biliary radicals by swollen and ballooned
hepatocytes[23] or interference with basolateral and
intracellular transport of bile acids[24] which may in
turn induce cholestasis[25]. Accordingly, a particular
bile acid pattern (elevated chenodeoxycholic and low
deoxycholic acid serum levels) has been reported in
patients with ASH [26], that correlated with histological
features in general, but not with cholestasis in particular.
This apparent dissociation between serum bile acids,
bilirubin and tissue cholestasis has been observed in
almost forty percent of the cohort described by Nissen-
baum et al.[9]. Supplementation of ursodeoxycholic acid
in patients with alcoholic cirrhosis and high serum bilir-
ubin is associated with a decrease in biological tests of
cholestasis [27] but histological changes are not
described. Whether intracellular and canalicular traffick-
ing of bile may be altered in ASH is a valid hypothesis.
Both sepsis and ASH are characterized by a dysregulated
inflammatory reaction with production of pro-inflamma-
tory cytokines[10,16,28]. In both conditions endotoxe-
mia may be detectable, TNFa is elevated, and bile flow
is impaired at the cellular level[13,29,30]. In a subgroup
of our patients, however, we were unable to demonstrate
any relationship between bilirubinostasis and TNFa
serum levels. Whether serum levels of cytokines truly
Table 3 Univariate analysis
Variable Cut-off P value
Age (yrs) ≥ 50
< 50 0.01
Pugh’s score ≥ 10
< 10 0.002
MELD score ≥ 19
< 19 0.001
Maddrey’s score ≥ 32
< 32 0.001




Neutrophilic infiltration ≥ 50%
< 50% 0.320
Hepatocellular damage ≥ 50%
< 50% 0.054
Ductular reaction ≥ 50%
< 50% 0.628
Iron deposits ≥ 50%
< 50% 0.137
ASAT (IU/L) ≥ 90
< 90 0.26
Alkaline phosphatase (IU/L) ≥ 160
< 160 0.83
Abbreviations: ASAT: aspartate amino transferase
Table 4 Multivariate analysis
Variable P OR 95% CI
Age 0.029 2.83 1.11-7.2
Intraparenchymal cholestasis 0.001 3.9 1.96-7.8
Maddrey’s score 0.027 3.93 1.17-13.23
Figure 5 Serum bilirubin levels according to the presence or
absence of marked bilirubinostasis on liver biopsy.
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reflect their biological activity within the hepatocyte is
questionable.
Except for lobular cholestasis, other histological features
were not associated with clinical outcome. Steatosis results
from recent, heavy alcohol intake[16,20]. Major steatotic
changes were present in the majority of patients, asso-
ciated with recent and heavy alcohol intoxication. In alco-
holic liver disease, the severity of steatosis predicts the
development of cirrhosis over a 4-year period[31], but the
short term significance of this feature in ASH is unknown.
In our personal experience, steatosis is reduced and even
disappears within weeks following decompensation in case
of sustained alcohol abstinence. Marked hepatocellular
damage as assessed by frequent Mallory-Denk bodies and
ballooned hepatocytes was highly prevalent (> 70%) but
not significantly related to short term mortality (p =
0.086). In a recent study on 54 alcoholic patients present-
ing as acute-on-chronic liver failure [32], the majority of
whom were admitted to the intensive care unit and devel-
oped infection, the presence of Mallory-Denk bodies and
ductular bilirubinostasis were predictors of in-hospital
mortality. In a large cohort of patients with ASH treated
with steroids, Mathurin et al [17] reported a better 1-year
survival in patients with marked liver neutrophilic infiltra-
tion compared to those without this histological finding.
Our results didn’t confirm this association, and we
hypothesize that an older age (55 years in our study versus
48 years in the study by Mathurin[17]), previously sug-
gested to play a role in glucocorticoid efficacy, as well as
inclusion of 27% of patients with non severe ASH in our
cohort may explain this difference. Elevated liver iron is
associated with accelerated fibrosis in alcoholics [33] and
increased long term mortality in patients with alcoholic
cirrhosis [34]. However, over a short time period in
patients with ASH and cirrhosis, marked iron deposits
didn’t influence survival. Hepatocellular regeneration is an
important point to consider in the evolution of decompen-
sated liver disease. Extensive necrosis and apoptosis, repli-
cative senescence of mature hepatocytes, toxicity of
alcohol and metabolites, deleterious effect of cholestasis
[35], may all participate in poor organ repair mechanisms
in cirrhosis with superimposed ASH[36]. The intensity of
the ductular reaction in the periportal region, considered
as representative of regeneration processes[37], was not
able to discriminate survivors and non survivors, consis-
tent with recent data[6].
The strengths of our study is a detailed analysis of a
large group of patients with a well-defined alcoholic liver
disease based on histological findings obtained very early
after hospital admission, presenting either in a severe or
non severe form of ASH, in whom we described the out-
come 3 months after clinical decompensation. Having
performed a semi-quantitative analysis of the severity of
lesions, we demonstrated a significant correlation
between one of these features and clinical outcome.
Accordingly, intrahepatic cholestasis is an independent
predictor of 3-month mortality, together with age and
the Maddrey’s score, a commonly used robust parameter
that includes serum bilirubin and prothrombin time[38].
We acknowledge that our study suffers from some limita-
tions. First, due to missing date, we were not able to
include modern prognostic markers such as the Lille[22]
or the Glasgow[39] scores, nor the C-reactive protein.
Whether intraparenchymal cholestasis combined with
the short-term evolution of serum bilirubin included in
the Lille score brings additional information on prognosis
remained to be explored. Secondly, our assessment of
intrahepatic cholestasis may be suboptimal with regards
to the semi-quantitative analysis, and the criticism may
be raised that conversion of a subjective observation (i.e.
lesion present in more or less than 50% of the biopsy)
into a categorical variable is arbitrary and subject to
inconsistency. However, we have tested the reproducibil-
ity of the scoring system and demonstrated an excellent
inter observer agreement between the two histopatholo-
gists. Thirdly, the prevalence of histological lesions in
alcoholic liver disease may be influenced by the timing of
liver biopsy in relation to clinical deterioration, as fea-
tures such as steatosis, hepatocyte ballooning and Mal-
loy-Denk bodies tend to be less prominent over time[40].
Therefore, it is questionable whether intralobular choles-
tasis would still be relevant if the liver biopsy had been
performed later in the course of the disease.
Conclusion
This detailed analysis of histological features observed
on liver biopsies of patients with ASH demonstrates
that among the full spectrum of lesions observed in
alcoholic liver disease, only marked intralobular choles-
tasis is closely associated with the short term clinical
outcome. It may be hypothesized that incorporation of
this variable into existing disease severity scores for
ASH would improve their performance.
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